2023 Chinese guideline for lipid management
Frontiers in Pharmacology · 29.08.2023 · 14
DOI: 10.3389/fphar.2023.1190934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.08.2023. Verfasst von Jian-Jun Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences, Beijing, China. Die Arbeit wurde bisher 217-mal zitiert (Crossref) und nennt 260 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of Chinese guideline for lipid management is imperative, especially since the target lipid levels in the general population vary in respect to the risk of ASCVD. The level of LDL-C, which can be regarded as appropriate in a population without frisk factors, can be considered abnormal in people at high risk of developing ASCVD. As a result, the “Guidelines for the prevention and treatment of dyslipidemia" were adapted into the “Chinese guideline for Lipid Management" (henceforth referred to as the new guidelines) by an Experts’ committee after careful deliberation. The new guidelines still recommend LDL-C as the primary target for lipid control, with cardiovascular disease (CVD) risk stratification to determine its target value. These guidelines recommend that moderate intensity statin therapy in adjunct with a heart-healthy lifestyle, be used as an initial line of treatment, followed by cholesterol absorption inhibitors or/and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as necessary. The new guidelines provide guidance for lipid management across various age groups, from children to the elderly. The aim of these guidelines is to comprehensively improve the management of lipids and promote the prevention and treatment of ASCVD by guiding clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Affiliated Hospital of Zunyi Medical University, School of Laboratory Medicine of Zunyi Medical University, Zunyi, Guizhou, China.
Zitieren
APA
Li, J. J., Zhao, S. P., Zhao, D., Lu, G. P., Peng, D. Q., Liu, J., Chen, Z. Y., Guo, Y. L., Wu, N. Q., Yan, S. K., Wang, Z. W., & Gao, R. L. (2023). 2023 Chinese guideline for lipid management. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1190934
Vancouver
Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 Chinese guideline for lipid management. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1190934
BibTeX
@article{Li2023,
author = {Li, Jian-Jun and Zhao, Shui-Ping and Zhao, Dong and Lu, Guo-Ping and Peng, Dao-Quan and Liu, Jing and Chen, Zhen-Yue and Guo, Yuan-Lin and Wu, Na-Qiong and Yan, Sheng-Kai and Wang, Zeng-Wu and Gao, Run-Lin},
title = {2023 Chinese guideline for lipid management},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1190934}
}
EUVIMED